KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

JOURNAL OF HYPERTENSION, published by Lippincott Williams & Wilkins, stands at the forefront of cardiovascular research, serving as a premier platform for the dissemination of knowledge in hypertension and related cardiovascular conditions. With an impressive impact factor, this esteemed journal is recognized in Q1 quartile across multiple categories, including Cardiology, Internal Medicine, and Physiology as of 2023, firmly establishing its significance within the academic community. The journal has been a reliable source of cutting-edge research since its inception in 1983, with continued publication through 2024. Researchers can expect a rigorous peer-review process and a diverse array of articles that include original research, reviews, and clinical studies aimed at enhancing the understanding and management of hypertension. Although it is not an open-access journal, the JOURNAL OF HYPERTENSION remains invaluable to clinicians, researchers, and students dedicated to advancing the field of cardiovascular health.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

BLOOD PRESSURE MONITORING is a distinguished academic journal published by Lippincott Williams & Wilkins, dedicated to advancing the study of blood pressure measurement and management across various medical disciplines. With an ISSN of 1359-5237 and an E-ISSN of 1473-5725, this journal has consistently contributed to the field since its inception in 1996, continuing to provide invaluable insights through 2024. Notably, the journal ranks in the Q2 quartile for Advanced and Specialized Nursing and Assessment and Diagnosis, illustrating its influence in these areas, while also making significant contributions to Cardiology, Internal Medicine, and broader Medical research. Although it does not currently offer open access, BLOOD PRESSURE MONITORING remains essential reading for researchers, healthcare professionals, and students, eager to stay at the forefront of blood pressure research and its critical implications in clinical practice. The journal's commitment to quality and rigor makes it a vital resource for anyone involved in the continuously evolving fields of cardiovascular health and patient monitoring.

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION is a premier academic journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and research in the fields of nephrology and hypertension. Since its inception in 1992, this journal has been an essential resource for professionals seeking to stay at the forefront of kidney health and blood pressure management. With a distinguished ranking in the top quartile (Q1) for both Internal Medicine and Nephrology as of 2023, the journal is recognized for its high impact, currently holding a Scopus rank of #16 out of 81 in Nephrology, positioning it in the 80th percentile. Although not an open access journal, it provides crucial insights and expert opinions that cater to researchers, clinicians, and students committed to improving patient outcomes through evidence-based practice. The journal continues to emphasize its objectives of disseminating pivotal findings and fostering discussions that bridge the gap between clinical practice and research, making it an invaluable asset in the evolving landscape of nephrology and hypertension.

JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.